Literature DB >> 25450259

Recent progress in microRNA delivery for cancer therapy by non-viral synthetic vectors.

Huiyuan Wang1, Yifan Jiang1, Huige Peng1, Yingzhi Chen1, Peizhi Zhu2, Yongzhuo Huang3.   

Abstract

MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression. Because of significant changes in their expression in cancer, miRNAs are believed to be key factors in cancer genetics and to have potential as anticancer drugs. However, the delivery of miRNAs is limited by many barriers, such as low cellular uptake, immunogenicity, renal clearance, degradation by nucleases, elimination by phagocytic immune cells, poor endosomal release, and untoward side effects. Nonviral delivery systems have been developed to overcome these obstacles. In this review, we provide insights into the development of non-viral synthetic miRNA vectors and the promise of miRNA-based anticancer therapies, including therapeutic applications of miRNAs, challenges of vector design to overcome the delivery obstacles, and the development of miRNA delivery systems for cancer therapy. Additionally, we highlight some representative examples that give a glimpse into the current trends into the design and application of efficient synthetic systems for miRNA delivery. Overall, a better understanding of the rational design of miRNA delivery systems will promote their translation into effective clinical treatments.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer therapy; Drug delivery; MicroRNA; Non-viral vector; Synthetic vector

Mesh:

Substances:

Year:  2014        PMID: 25450259     DOI: 10.1016/j.addr.2014.10.031

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  61 in total

Review 1.  MicroRNAs as novel endogenous targets for regulation and therapeutic treatments.

Authors:  Wenzhang Cha; Rengen Fan; Yufeng Miao; Yong Zhou; Chenglin Qin; Xiangxiang Shan; Xinqiang Wan; Ting Cui
Journal:  Medchemcomm       Date:  2017-12-11       Impact factor: 3.597

Review 2.  MicroRNAs in injury and repair.

Authors:  Cory V Gerlach; Vishal S Vaidya
Journal:  Arch Toxicol       Date:  2017-05-13       Impact factor: 5.153

Review 3.  Involvement of microRNAs in HER2 signaling and trastuzumab treatment.

Authors:  Ling Mao; Ai-Jun Sun; Jian-Zhong Wu; Jin-Hai Tang
Journal:  Tumour Biol       Date:  2016-10-12

Review 4.  Therapeutic prospects of microRNAs in cancer treatment through nanotechnology.

Authors:  Rajendra Awasthi; Michael John Rathbone; Philip Michael Hansbro; Mary Bebawy; Kamal Dua
Journal:  Drug Deliv Transl Res       Date:  2018-02       Impact factor: 4.617

Review 5.  Exploiting microRNAs As Cancer Therapeutics.

Authors:  Tamsin Robb; Glen Reid; Cherie Blenkiron
Journal:  Target Oncol       Date:  2017-04       Impact factor: 4.493

Review 6.  MicroRNAs as therapeutics for future drug delivery systems in treatment of lung diseases.

Authors:  Kamal Dua; Nicole G Hansbro; Paul S Foster; Philip M Hansbro
Journal:  Drug Deliv Transl Res       Date:  2017-02       Impact factor: 4.617

Review 7.  [The role of microRNAs in head and neck squamous cell carcinoma : Biomarkers for prognosis, therapy selection, and novel therapeutics].

Authors:  A K Heß; W Weichert; V Budach; I Tinhofer
Journal:  HNO       Date:  2016-05       Impact factor: 1.284

Review 8.  Towards nanomedicines of the future: Remote magneto-mechanical actuation of nanomedicines by alternating magnetic fields.

Authors:  Yuri I Golovin; Sergey L Gribanovsky; Dmitry Y Golovin; Natalia L Klyachko; Alexander G Majouga; Аlyssa M Master; Marina Sokolsky; Alexander V Kabanov
Journal:  J Control Release       Date:  2015-09-25       Impact factor: 9.776

Review 9.  Importance of integrating nanotechnology with pharmacology and physiology for innovative drug delivery and therapy - an illustration with firsthand examples.

Authors:  Rui Xue Zhang; Jason Li; Tian Zhang; Mohammad A Amini; Chunsheng He; Brian Lu; Taksim Ahmed; HoYin Lip; Andrew M Rauth; Xiao Yu Wu
Journal:  Acta Pharmacol Sin       Date:  2018-04-26       Impact factor: 6.150

10.  miRNA-182 and the regulation of the glioblastoma phenotype - toward miRNA-based precision therapeutics.

Authors:  Fotini M Kouri; Carissa Ritner; Alexander H Stegh
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.